Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.15 USD
Change Today 0.00 / 0.00%
Volume 0.0
PGLA On Other Exchanges
As of 8:10 PM 08/24/15 All times are local (Market data is delayed by at least 15 minutes).

progen pharmaceuticals ltd (PGLA) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/3/14 - $0.27
52 Week Low
04/10/15 - $0.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

progen pharmaceuticals ltd (PGLA) Related Businessweek News

No Related Businessweek News Found

progen pharmaceuticals ltd (PGLA) Details

Progen Pharmaceuticals Limited, a biotechnology company, discovers, researches, and develops biopharmaceutical therapeutics for the treatment of human diseases in Australia and the United States. It focuses on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The company’s products in research and development stage include PG545, an anti-cancer compound in preclinical development; and PI-88 melanoma program that is in Phase III clinical trial in post-resection liver cancer. It also provides contract services related to the process development, manufacture, and quality assurance of biological products. Progen Pharmaceuticals Limited is based in Darra, Australia.

progen pharmaceuticals ltd (PGLA) Top Compensated Officers

Executive Chairman, Chairman of Remuneration ...
Total Annual Compensation: A$80.0K
Chief Executive Officer of PharmaSynth Pty Lt...
Total Annual Compensation: A$169.3K
Company Secretary
Total Annual Compensation: A$59.0K
Director of Legal & Business Development
Total Annual Compensation: A$185.3K
Director of Drug Development
Total Annual Compensation: A$186.1K
Compensation as of Fiscal Year 2015.

progen pharmaceuticals ltd (PGLA) Key Developments

Progen Pharmaceuticals Ltd Announces Director Changes

Progen Pharmaceuticals Ltd. announced the appointment of Dr. Christopher Harvey as an independent Non-Executive Director. Dr. Harvey is currently the Chairman of Global Speciality Chemicals Pty Ltd. and HealthGuard Corporation Pty Ltd. Further, Mr. Heng Tang has resigned from his roles as Managing Director of PharmaSynth Pty Ltd. and Director of the Company to pursue other business interests.

Progen Pharmaceuticals Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Progen Pharmaceuticals Limited reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported revenue of AUD 2,549,909 against AUD 1,354,906 a year ago. Loss before income tax expense was AUD 2,045,104 against AUD 1,962,310 a year ago. Net loss for the period was AUD 2,045,104 or 3.70 cents per basic and diluted share against AUD 1,962,310 or 3.55 cents per basic and diluted share a year ago. Net cash flows used in operating activities was AUD 1,755,002 against AUD 1,849,751 a year ago. Purchase of plant and equipment was AUD 295,756 against AUD 263,964 a year ago.

Progen Pharmaceuticals Provides Clinical Trial Update on PI-88

Progen Pharmaceuticals Ltd. provided the information on the PI-88 PATRON clinical trial received from its licensee, Medigen Biotechnology Corporation (‘Medigen’). On 26 January 2015, the Medigen Board of Directors resolved to bring forward the analysis of PI-88 Phase III PATRON clinical trial data, and will inform the Taiwan Food and Drug Administration (“TFDA”) of this decision. As of 26 January 2015, all 520 patients in the PATRON trial have completed treatment with either PI-88 or the placebo. The PATRON clinical trial is a Phase III randomised, placebo-controlled trial being conducted in Taiwan, South Korea, China and Hong Kong to confirm the safety and efficacy of PI-88 in the adjuvant treatment of hepatocellular carcinoma after surgical resection. Pursuant to the clinical trial design, patients were to be treated for 12 months with either PI-88 or the placebo and receive follow-up for two years. Following this decision by the Medigen Board, other than patients receiving antiviral therapy, the patients will not receive any further follow-up beyond a final study visit to be conducted within the next 28 days. Medigen will now execute a study conclusion plan for the PATRON trial with the clinical trial sites and investigators. After the collection of the clinical data, a comprehensive statistical analysis will be carried out and a final clinical study report prepared. The final clinical study report will be submitted to TFDA after the completion of data collection and analysis. Medigen will make a decision on the next phase of PI-88 based on the final result of data analysis and discussion with regulatory authorities.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGLA:US $0.15 USD 0.00

PGLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PGLA.
View Industry Companies

Industry Analysis


Industry Average

Valuation PGLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGEN PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at